name	nt_name	aa_name	multi_aa_name	multiaa_comb_mutation	start	vcf_gene	chrom_region	mutation_type	sequence_depth	sample_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao	reference_seq	variant_seq	viral_lineages	function_category	citation	comb_mutation	function_description	heterozygosity	clade_defining	who_variant	status	voi_designation_date	voc_designation_date	vum_designation_date
c.-3delA	c.-3delA				28270	N	intergenic		8	8						0	8	TA	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
c.C-25T	c.C-25T				241	orf1ab	5' UTR		8	8						0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
c.C-5T	c.C-5T				27389	ORF7a	intergenic		8	8						7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
c.G-12T	c.G-12T				27882	ORF8	intergenic		8	8						0	8	G	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
c.G-47A	c.G-47A				219	orf1ab	5' UTR		8	8						7	1	G	A	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
c.G29692A	c.G*4308A				29692	intergenic	3' UTR		8	8						7	1	G	A	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
c.G29742T	c.G*4358T				29742	intergenic	Stem-loop,3' UTR		8	8						7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.A3924V	c.C11771T	p.A3924V			12036	orf1ab	ORF1ab	MISSENSE	8	8			nsp7	produced by both pp1a and pp1ab	YP_009725303.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.A4921V	c.C14762T	p.A4921V			15026	orf1ab	ORF1ab	MISSENSE	8	8			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	6	2	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.A5844V	c.C17531T	p.A5844V			17795	orf1ab	ORF1ab	MISSENSE	8	8			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.A859V	c.C2576T	p.A859V			2841	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.A899S	c.G2695T	p.A899S			24257	S	S	MISSENSE	8	8						0	8	G	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.A99T	c.G295A	p.A99T			25687	ORF3a	ORF3a	MISSENSE	8	8						7	1	G	A	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.D1146N	c.G3436A	p.D1146N			24998	S	S	MISSENSE	8	8						7	1	G	A	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.D1184D	c.C3552T	p.D1184D			3817	orf1ab	ORF1ab	SILENT	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.D1639N	c.G4915A	p.D1639N			5180	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	8	G	A	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.D2980N	c.G8938A	p.D2980N			9203	orf1ab	ORF1ab	MISSENSE	8	8			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	8	G	A	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.D31Y	c.G91T	p.D31Y			29648	ORF10	ORF10	MISSENSE	8	8						7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.D3222N	c.G9664A	p.D3222N			9929	orf1ab	ORF1ab	MISSENSE	8	8			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	8	G	A	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.D5429Y	c.G16285T	p.D5429Y			16549	orf1ab	ORF1ab	MISSENSE	8	8			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	8	G	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.D6069D	c.T18207C	p.D6069D			18471	orf1ab	ORF1ab	SILENT	8	8			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	7	1	T	C	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	ACE2 receptor binding affinity	Gong et al. (2021)	'H69del', 'V70del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	ACE2 receptor binding affinity	Gong et al. (2021)	'L452R'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	ACE2 receptor binding affinity	Li et al. (2020)		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	convalescent plasma binding	Gong et al. (2021)	'H69del', 'V70del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	convalescent plasma binding	Gong et al. (2021)	'L452R'	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	convalescent plasma escape	Wilhelm et al. (2021)	'L452R'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	immunosuppression variant emergence	Landis et al. (2021)		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	syncytium formation	Kim et al. (2021)		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	tissue specific neutralization	Planas et al. (2021)		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	trafficking	Barrett et al. (2021)		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	trafficking	Daniloski et al. (2021)		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	trafficking	Kim et al. (2021)		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	trafficking	Kim et al. (2021)		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	trafficking	Ozono et al. (2020)		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	trafficking	Zhang et l. (2020)		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	transmissibility	Tada et al. (2021)	'L452R'	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase]	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	vaccine neutralization efficacy	Kuzmina et al. (2021)		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	vaccine neutralization efficacy	Wilhelm et al. (2021)	'L452R'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	vaccinee plasma binding	Gong et al. (2021)	'H69del', 'V70del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	vaccinee plasma binding	Gong et al. (2021)	'L452R'	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	viral load	Plante et al. (2020)		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	virion structure	Weissman et al. (2020)		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	virion structure	Yurkovetskiy et al. (2020)		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Unnamed	VUM			16-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	8	8						0	8	A	G	C.36.3	virion structure	Zhang et al. (2020)		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	True	Unnamed	VUM			16-Jun-2021
p.E102K	c.G304A	p.E102K			569	orf1ab	ORF1ab	MISSENSE	8	8			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	8	G	A	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.E10D	c.G30T	p.E10D			295	orf1ab	ORF1ab	MISSENSE	8	8			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.E2089D	c.G6267T	p.E2089D			6532	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.E5643D	c.G16929T	p.E5643D			17193	orf1ab	ORF1ab	MISSENSE	8	8			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.E6378D	c.G19134T	p.E6378D			19398	orf1ab	ORF1ab	MISSENSE	8	8			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.G212V	c.G635T	p.G212V			28908	N	N	MISSENSE	8	8						0	8	G	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.G261V	c.G782T	p.G261V			22344	S	S	MISSENSE	8	8						7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.G3278S	c.G9832A	p.G3278S			10097	orf1ab	ORF1ab	MISSENSE	8	8			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	8	G	A	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.G4374S	c.G13120A	p.G4374S			13385	orf1ab	ORF1ab	MISSENSE	8	8			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab	YP_009725306.1	7	1	G	A	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.G70G	c.C210T	p.G70G			27603	ORF7a	ORF7a	SILENT	8	8						7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.H1083H	c.T3249C	p.H1083H			24811	S	S	SILENT	8	8						4	4	T	C	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.H69del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'V70del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'V70del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	True	Unnamed	VUM			16-Jun-2021
p.H69del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'V70del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	antibody epitope effects	Rees-Spear et al. (2021)	'V70del'	Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).	False	True	Unnamed	VUM			16-Jun-2021
p.H69del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'V70del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	convalescent plasma binding	Gong et al. (2021)	'D614G', 'V70del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	True	Unnamed	VUM			16-Jun-2021
p.H69del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'V70del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	convalescent plasma escape	Kemp et al. (2020)		Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma	False	True	Unnamed	VUM			16-Jun-2021
p.H69del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'V70del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	convalescent plasma escape	Shen et al. (2021)	'V70del'	Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.	False	True	Unnamed	VUM			16-Jun-2021
p.H69del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'V70del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	convalescent plasma escape	Tada et al. (2021)	'V70del'	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	True	Unnamed	VUM			16-Jun-2021
p.H69del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'V70del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	immunosuppression variant emergence	Kemp et al. (2020)		The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.	False	True	Unnamed	VUM			16-Jun-2021
p.H69del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'V70del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'V70del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			16-Jun-2021
p.I3853I	c.C11559T	p.I3853I			11824	orf1ab	ORF1ab	SILENT	8	8			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.I82T	c.T245C	p.I82T			26767	M	M	MISSENSE	8	8						0	8	T	C	C.36.3	homoplasy	Shen et al. (2021)		This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds.	False	True	Unnamed	VUM			16-Jun-2021
p.K256R	c.A767G	p.K256R			29040	N	N	MISSENSE	8	8						4	4	A	G	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.L1313L	c.C3937T	p.L1313L			4202	orf1ab	ORF1ab	SILENT	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.L3691S	c.T11072C	p.L3691S			11337	orf1ab	ORF1ab	MISSENSE	8	8			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	8	T	C	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	ACE2 receptor binding affinity	Motozono et al. (2021)		~1.7-fold increase in binding affinity vs wild type.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	T cell evasion	Motozono et al. (2021)		L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	antibody epitope effects	Li et al. (2020)		Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	antibody epitope effects	Liu et al. (2021)		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	antibody epitope effects	McCallum et al. (2021)		10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	antibody epitope effects	Sun et al. (2021)		~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	convalescent plasma binding	Gong et al. (2021)	'D614G'	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	convalescent plasma escape	Alenquer et al. (2021)		Observed ~2x decrease on average in 16 health workers' convalescent sera.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	convalescent plasma escape	Liu et al. (2021)		Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	convalescent plasma escape	Wilhelm et al. (2021)	'D614G'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	gene expression increase	Starr et al. (2020)		Experimentally, Spike gene expression increased 0.32 fold	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	monoclonal antibody serial passage escape	Greaney et al. (2020)		Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	monoclonal antibody serial passage escape	Starr et al. (2021)		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	monoclonal antibody serial passage escape	Wang et al. (2021)		Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	pharmaceutical effectiveness	Engelhart et al. (2021)		Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	pharmaceutical effectiveness	McCallum et al. (2021)		Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	trafficking	Deng et al. (2021)		We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	trafficking	Ferriera et al (2021)		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4]	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	trafficking	Motozono et al. (2021)		Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	transmissibility	Tada et al. (2021)	'D614G'	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase]	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	vaccine neutralization efficacy	Ferreira et al. (2021)		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	vaccine neutralization efficacy	Jacobson et al. (2021)		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	vaccine neutralization efficacy	Wilhelm et al. (2021)	'D614G'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			16-Jun-2021
p.L452R	c.T1355G	p.L452R			22917	S	S	MISSENSE	8	8						0	8	T	G	C.36.3	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type) 	False	True	Unnamed	VUM			16-Jun-2021
p.N1709N	c.C5127T	p.N1709N			5392	orf1ab	ORF1ab	SILENT	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.N192N	c.C576T	p.N192N			28849	N	N	SILENT	8	8						7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.N25N	c.C75T	p.N25N			29632	ORF10	ORF10	SILENT	8	8						3	5	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.N6333S	c.A18998G	p.N6333S			19262	orf1ab	ORF1ab	MISSENSE	8	8			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	7	1	A	G	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.P2287S	c.C6859T	p.P2287S			7124	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	8	8			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.P5853L	c.C17558T	p.P5853L			17822	orf1ab	ORF1ab	MISSENSE	8	8			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	4	4	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.Q6279H	c.G18837T	p.Q6279H			19101	orf1ab	ORF1ab	MISSENSE	8	8			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.R158L	c.G473T	p.R158L			26995	M	M	MISSENSE	8	8						7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.R346S	c.A1038C	p.R346S			22600	S	S	MISSENSE	8	8						0	8	A	C	C.36.3	antibody epitope effects	Gaebler et al. (2021)		Clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	True	Unnamed	VUM			16-Jun-2021
p.R346S	c.A1038C	p.R346S			22600	S	S	MISSENSE	8	8						0	8	A	C	C.36.3	antibody epitope effects	Wang et al. (2021)		Resistent to class 2/3 antibody C603.	False	True	Unnamed	VUM			16-Jun-2021
p.R346S	c.A1038C	p.R346S			22600	S	S	MISSENSE	8	8						0	8	A	C	C.36.3	monoclonal antibody serial passage escape	Weisblum et al. (2020)		Positive selection (up to 30% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M	False	True	Unnamed	VUM			16-Jun-2021
p.R7014S	c.C21040A	p.R7014S			21304	orf1ab	ORF1ab	MISSENSE	8	8	caution	neighbour_linked	2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	7	1	C	A	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.RG203KR	c.GGG608_610AAC	p.RG203KR			28881	N	N		8	8						0	8	GGG	AAC	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.S12F	c.C35T	p.S12F			21597	S	S	MISSENSE	8	8						0	8	C	T	C.36.3	antibody epitope effects	McCallum et al. (2021)		A variant in low % circulation, predicted to have a similar effect to the experimentally verified S12P, which introduces a new signal peptide, altering cleavage to occur between residues C15 and V16, thereby eliminating the C15-C136 disulfide bond – similarly to escape mutants at positions C15 and C136. This in turn decreases to varying degrees N terminal domain antigen recognition by supersite i mAbs S2L28, S2M28, S2X28, S2X333, 4A8.	False	True	Unnamed	VUM			16-Jun-2021
p.S2556L	c.C7667T	p.S2556L			7932	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.S3687L	c.C11060T	p.S3687L			11325	orf1ab	ORF1ab	MISSENSE	8	8			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.S443F	c.C1328T	p.S443F			1593	orf1ab	ORF1ab	MISSENSE	8	8			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	7	1	C	T	C.36.3	monoclonal antibody serial passage escape	Greaney et al. (2020)		Ranked effective escape variant in the RBD for highly neutralizing COV2-2499 monoclonal antibody	False	False	Unnamed	VUM			16-Jun-2021
p.S68S	c.T204C	p.S68S			26448	E	E	SILENT	8	8						7	1	T	C	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.T1017I	c.C3050T	p.T1017I			3315	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.T1055I	c.C3164T	p.T1055I			3429	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.T1246I	c.C3737T	p.T1246I			4002	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.T1854I	c.C5561T	p.T1854I			5826	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.T2967I	c.C8900T	p.T2967I			9165	orf1ab	ORF1ab	MISSENSE	8	8			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.T4090I	c.C12269T	p.T4090I			12534	orf1ab	ORF1ab	MISSENSE	8	8			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.T5805M	c.C17414T	p.T5805M			17678	orf1ab	ORF1ab	MISSENSE	8	8			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.T5941I	c.C17822T	p.T5941I			18086	orf1ab	ORF1ab	MISSENSE	8	8			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.T5975T	c.C17925T	p.T5975T			18189	orf1ab	ORF1ab	SILENT	8	8			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	4	4	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.T723T	c.C2169T	p.T723T			23731	S	S	SILENT	8	8						0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.V2421V	c.C7263T	p.V2421V			7528	orf1ab	ORF1ab	SILENT	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.V4073V	c.C12219T	p.V4073V			12484	orf1ab	ORF1ab	SILENT	8	8			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.V5834V	c.C17502T	p.V5834V			17766	orf1ab	ORF1ab	SILENT	8	8			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.V62V	c.G186T	p.V62V			28079	ORF8	ORF8	SILENT	8	8						7	1	G	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.V70del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'H69del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G', 'H69del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	True	Unnamed	VUM			16-Jun-2021
p.V70del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'H69del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	antibody epitope effects	Rees-Spear et al. (2021)	'H69del'	Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).	False	True	Unnamed	VUM			16-Jun-2021
p.V70del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'H69del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	convalescent plasma binding	Gong et al. (2021)	'D614G', 'H69del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	True	Unnamed	VUM			16-Jun-2021
p.V70del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'H69del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	convalescent plasma escape	Kemp et al. (2020)		Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma	False	True	Unnamed	VUM			16-Jun-2021
p.V70del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'H69del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	convalescent plasma escape	Shen et al. (2021)	'H69del'	Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.	False	True	Unnamed	VUM			16-Jun-2021
p.V70del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'H69del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	convalescent plasma escape	Tada et al. (2021)	'H69del'	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	True	Unnamed	VUM			16-Jun-2021
p.V70del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'H69del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	immunosuppression variant emergence	Kemp et al. (2020)		The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.	False	True	Unnamed	VUM			16-Jun-2021
p.V70del	c.203_208delTACATG	p.H69_V70del	H69_V70del	'H69del'	21764	S	S		6	8						0	6	ATACATG	A	C.36.3	vaccinee plasma binding	Gong et al. (2021)	'D614G', 'H69del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			16-Jun-2021
p.W152R	c.T454A	p.W152R			22016	S	S	MISSENSE	14	8						0	14	T	A	C.36.3, C.36.3					False	True, True	Unnamed	VUM			16-Jun-2021
p.Y113H	c.T337C	p.Y113H			25729	ORF3a	ORF3a	MISSENSE	8	8						7	1	T	C	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.Y4424Y	c.C13272T	p.Y4424Y			13536	orf1ab	ORF1ab	SILENT	8	8			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	8	C	T	C.36.3					False	True	Unnamed	VUM			16-Jun-2021
p.Y6079Y	c.C18237T	p.Y6079Y			18501	orf1ab	ORF1ab	SILENT	8	8			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	7	1	C	T	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
p.Y947H	c.T2839C	p.Y947H			3104	orf1ab	ORF1ab	MISSENSE	8	8			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	1	T	C	C.36.3					False	False	Unnamed	VUM			16-Jun-2021
